131 related articles for article (PubMed ID: 17875802)
1. Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer.
Paganelli G; Ferrari M; Ravasi L; Cremonesi M; De Cicco C; Galimberti V; Sivolapenko G; Luini A; De Santis R; Travaini LL; Fiorenza M; Chinol M; Papi S; Zanna C; Carminati P; Veronesi U
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5646s-5651s. PubMed ID: 17875802
[TBL] [Abstract][Full Text] [Related]
2. IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation.
Paganelli G; Ferrari M; Cremonesi M; De Cicco C; Galimberti V; Luini A; Veronesi P; Fiorenza M; Carminati P; Zanna C; Orecchia R; Veronesi U
Breast; 2007 Feb; 16(1):17-26. PubMed ID: 17174093
[TBL] [Abstract][Full Text] [Related]
3. 3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART) combined with external beam radiation therapy.
Ferrari ME; Cremonesi M; Di Dia A; Botta F; De Cicco C; Sarnelli A; Pedicini P; Calabrese M; Orecchia R; Pedroli G; Paganelli G
Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1702-11. PubMed ID: 22890802
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with (90)Y-labeled biotin.
Paganelli G; De Cicco C; Ferrari ME; Carbone G; Pagani G; Leonardi MC; Cremonesi M; Ferrari A; Pacifici M; Di Dia A; De Santis R; Galimberti V; Luini A; Orecchia R; Zurrida S; Veronesi U
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):203-11. PubMed ID: 19760414
[TBL] [Abstract][Full Text] [Related]
5. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
6. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
7. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
8. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and biodistribution of [111In]-avidin and [99mTc]-biotin-liposomes injected in the pleural space for the targeting of mediastinal nodes.
Medina LA; Klipper R; Phillips WT; Goins B
Nucl Med Biol; 2004 Jan; 31(1):41-51. PubMed ID: 14741569
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy confined to the tumor bed following breast conserving surgery current status, controversies, and future projects.
Polgár C; Fodor J; Major T; Takácsi-Nagy Z; Kásler M; Hammer J; Van Limbergen E; Németh G
Strahlenther Onkol; 2002 Nov; 178(11):597-606. PubMed ID: 12426670
[TBL] [Abstract][Full Text] [Related]
12. Early breast cancer treated with conservative surgery, adjuvant chemotherapy, and delayed accelerated partial breast irradiation with high-dose-rate brachytherapy.
Gómez-Iturriaga A; Pina L; Cambeiro M; Martínez-Regueira F; Aramendía JM; Fernández-Hidalgo O; Martínez-Monge R
Brachytherapy; 2008; 7(4):310-5. PubMed ID: 18778971
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
Cremonesi M; Ferrari M; Chinol M; Bartolomei M; Stabin MG; Sacco E; Fiorenza M; Tosi G; Paganelli G
Q J Nucl Med; 2000 Dec; 44(4):325-32. PubMed ID: 11302260
[TBL] [Abstract][Full Text] [Related]
14. Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm.
Albertoni C; Leoni B; Rosi A; D'Alessio V; Carollo V; Spagnoli LG; van Echteld C; De Santis R
Cancer Biother Radiopharm; 2015 Sep; 30(7):291-8. PubMed ID: 26167947
[TBL] [Abstract][Full Text] [Related]
15. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study.
Reitsamer R; Peintinger F; Kopp M; Menzel C; Kogelnik HD; Sedlmayer F
Strahlenther Onkol; 2004 Jan; 180(1):38-44. PubMed ID: 14704843
[TBL] [Abstract][Full Text] [Related]
16. IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin.
Paganelli G; De Cicco C; Ferrari ME; McVie G; Pagani G; Leonardi MC; Cremonesi M; Ferrari A; Pacifici M; Di Dia A; Botta F; De Santis R; Galimberti V; Luini A; Orecchia R; Veronesi U
Ecancermedicalscience; 2010; 4():166. PubMed ID: 22276027
[TBL] [Abstract][Full Text] [Related]
17. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
19. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
20. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
